Search Follow us

Celyad (CYAD)

Business description

Celyad is developing an innovative Natural Killer Receptor CAR T-cell therapy (CYAD-01). This focuses on AML and metastatic colorectal cancer. A comprehensive set of clinical studies is underway.

Stock data

Market cap.€213.8m
Last close€17.90
High / Low (52 weeks)€34.3 / €15.5
Stock market listingEU
Forecast net cash (€m)45.9
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceuticals & healthcare

Price performance

%1m3m12m
Actual(7.4)(25.5)(47.1)
Relative *(10.8)(25.1)(41.5)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Actinogen Medical Active Biotech
Acucela Addex Therapeutics
Adherium ADL Bionatur Solutions
Adocia Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Antibe Therapeutics
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASIT biotech
ASLAN Pharmaceuticals Astex Pharmaceuticals
Athersys Atossa Genetics
Auris Medical Holding Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Avivagen
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLargo
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma BioPorto Diagnostics
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics Bonesupport
BrainStorm Cell Therapeutics Brighter
BTG C4X Discovery Holdings
Caladrius Biosciences Can-Fite BioPharma
CannTrust Holdings Cantargia
Capstone Therapeutics Carmat
CASI Pharmaceuticals Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Cerulean Pharma
Circadian Technologies Circassia Pharmaceuticals
Clal Biotechnology Industries Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel CO.DON
CollPlant Holdings Consort Medical
Corium International Crescendo
Crossject CSL
Curetis NV Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Deinove
Delcath Systems Deltex Medical
Derma Sciences Destiny Pharma
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Elbit Medical Technologies
Ellex Medical Lasers Emergent BioSolutions
Endocyte Epigenomics
Ergomed Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
Expedeon EyeGate Pharmaceuticals
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genkyotex
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Heat Biologics Inc.
Heidelberg Pharma Herantis Pharma
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Immutep Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals InflaRx
InMed Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
Japan Tobacco KaloBios Pharmaceuticals
Kane Biotech Karolinska Development
Kazia Therapeutics Keryx Biopharmaceuticals
Kiadis Pharma Laboratorios Farmacéuticos ROVI
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medicure Medigene
MedinCell Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MGC Pharmaceuticals Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncology Venture Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
OSE Immunotherapeutics Ossur
OvaScience OWL
Oxford BioMedica Oxford Immunotec
Pacific Edge Paion
Paladin Labs Patheon
PBKM PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shield Therapeutics
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
Telix Pharmaceuticals TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics True Leaf
TruScreen TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2016A 8.5 (21.2) (20.0) (209.0) N/A N/A
2017A 3.5 (22.3) (26.8) (279.0) N/A N/A
2018E 0.0 (26.5) (27.3) (243.0) N/A N/A
2019E 0.0 (27.8) (28.5) (238.0) N/A N/A

Last updated on 19/12/2018

Investment summary

Data at ASH in December confirmed that CYAD-01 T-cells can destroy acute myeloid leukaemia (AML) blast (cancer) cells. In data so far, CYAD-01 showed 62% (5/8) anti-leukemic activity across three dose levels including 38% (3/8) with some form of complete response. Safety was excellent with one, resolved, MTD. Further data are promised in H119, probably mid-year. In solid cancers, a study combining CYAD-01 with preconditioning is underway and may be crucial. The alloSHRINK allogeneic (CYAD-101) trial in mCRC dosed its first patient in November. This gives Celyad the lead in a mass-market solid cancer, where allogeneic therapy is likely to be essential. Celyad had €55.9m cash on 30 Sept. The H118 operational cash outflow was €13.9m.

Last updated on 01/02/2019

Industry outlook

CAR T-cell therapeutics remain a hot area for investment with increasing interest in the next stage of allogeneic products, where Celyad holds a key patent. Celyad remains in a key position in both AML and mCRC with a strong programme in solid tumours.

Last updated on 01/02/2019

Key management

Michel Lussier, Chairman
Dr Christian Homsy, CEO
Filippo Petti, CFO
Dr Gaëtane Metz, COO

Company address

Rue Edouard Belin 12
1435 Mont-Saint-Guibert
Belgium
+32(0)10 39 41 00
View website